Director Regulatory Affairs
Kerstin joined the company with the acquisition of Sividon Diagnostics GmbH in June 2016 and assumed responsibility for Regulatory Affairs for the diagnostic kit business. As a cofounder and head of RA/QA of Sividon, she implemented and maintained an ISO 13485 certified QM system. In addition, she had the regulatory responsibility for CE marking the EndoPredict test as well as preparing a 510(k) submission to FDA for this test. She obtained a PhD in molecular biology and spent several years of academic research in renowned research institutes (EMBL in Heidelberg, Max-Planck-Institute for Developmental Biology in Tuebingen). Since 2000, she held different positions in research, development and project management in the diagnostic industry at Bayer Healthcare, Siemens and Sividon in Germany and the United States.
Country Manager de Italia
Country Manager DACH (Germany, Austria and Switzerland)
Fani Kalaitsidis joined the company in January 2012 and has been appointed Country Manager DACH in July 2016. Fani has more than 16 years of healthcare experience and extensive knowledge in developing and implementing strategic plans to drive commercial growth in the life sciences, biotechnology, and diagnostic industries. Prior to joining Myriad, she held several positions at Baxter AG in the Bioscience care business. Fani is an accomplished senior executive experienced in positioning commercial companies for growth, profitability, and sustainable competitive advantage.
Fani received her Bachelor’s degree in Biology and Anthropology from Zurich University and her Executive Master’s degree of Business and Administration in General Management from St. Gallen University, Switzerland.
Gary A. King
Vicepresidente ejecutivo, Operaciones Internacionales
Country Manager France
Director, International Medical Affairs
Ralf Kronenwett joined Myriad Genetics with the acquisition of Sividon Diagnostics in June 2016 and holds the position of Director Medical Affairs and Clinical Development Kits. He received his medical degree from the University of Heidelberg. After serving as a resident physician at the University Hospital Heidelberg, Ralf Kronenwett was a research group leader at the Clinical Cooperation Unit Molecular Hematology/Oncology of the German Cancer Research Centre in Heidelberg. In 1999, he moved to the University Hospital Dusseldorf, qualified as an Assistant Professor of Molecular Medicine and focused on molecular therapeutics and diagnostics in hematology/oncology as well as biology and therapeutic use of hematopoietic stem cells. From 2006 to 2010, he held positions as senior scientist at Bayer HealthCare and Siemens Healthcare Diagnostics and was working on prognostic and predictive biomarkers in breast cancer. In 2010, Ralf Kronenwett founded together with former colleagues at Siemens the company Sividon Diagnostics GmbH as a “management buyout” and held the positions of the Chief Medical Officer and Chief Scientific Officer (CMO/CSO). He was responsible for Medical Affairs, for R&D activities and for the development of the breast cancer prognosis test EndoPredict. Ralf Kronenwett was involved in several international research projects and is a coauthor of more than 90 research journal publications.
Director of International Distribution
Director Customer and Kits Operations
Frank Nowas has worked in various roles within the In-Vitro-Diagnostics and Life Science industry for 21 years. After many years in technical field service and product support functions with Beckman Coulter in Europe, he became European Project Manager for laboratory automation and led later on the Clinical Diagnostics Service Germany West. He then spent nearly five years with the German subsidiary of Waters Inc. as National Service Manager. There he managed Field Service, Customer Support and Customer training. Excellent customer service for clinical customers, pharmaceutical and chemistry industry, universities and public institutions have been the main focus of his work there. Most recently, Mr. Nowas served as Director Services International in the area of gastroenterology. His responsibilities contained optimization of customer service for direct customers and distributors throughout the world, continuous improvement to the repair center as well as creating technical support capabilities outside Europe.
Mr. Nowas received his diploma in Biomedical Engineering from the University of Applied Science in Aachen.
Canadian Sales and Business Unit Manager
Managing Director Europe – Chief Commercial Officer
Jan Schlüchter joined the company in October 2015. As Managing Director Europe and Chief Commercial Officer, he oversees Country Operations across Europe. Jan has held several senior positions at Novartis over the past 12 years. Most recently, he served as Global Head of Key Account Management at Novartis’ headquarters in Basel, Switzerland. Previously, he held General Management roles in Greece and Germany.
Before Novartis, Jan was a Consultant at McKinsey and has founded two companies. He received his master’s degree in management from the University of Nuremberg, Germany and his doctor of philosophy degree in marketing from the University of Dortmund, Germany.
Country Manager Reino Unido e Irlanda
David inició su carrera científica trabajando en descubrimiento de fármacos después de un doctorado y una investigación postdoctoral en química orgánica sintética. Después de unos años en farmacoquímica, David pasó a un puesto más comercial, antes de entrar en Fisher Scientific UK Ltd como representante comercial. Tras un MBA en el Imperial College de Londres orientado hacia la atención sanitaria, David fichó por MeadWestvaco, un fabricante de envases líder mundial en su sector. Allí, desempeñó labores de desarrollo de negocio y ascendió hasta el puesto de Director Comercial Europeo del segmento “Adherence Packaging and Pump Dispenser”. Desde allí pasó a Thermo Fisher Scientific como responsable para Reino Unido, Irlanda y Países Bajos de las actividades de Diagnóstico Clínico. Desde este puesto, combinó con éxito el novedoso segmento de biomarcadores con la cartera, más consolidada, de drogas adictivas y controles de calidad. David tiene una dilatada experiencia en acceso a los mercados del Reino Unido, después de trabajar estrechamente con NICE, NIHR Diagnostic Evidence Cooperatives y el sistema público de salud de Inglaterra. Posee experiencia en Economía de la salud, modelización del impacto de decisiones y procesos de definición de directrices.